Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

TAK-063

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia
Review
2018
Review
2018
TAK‐063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia
The basal ganglia regulates motor, cognitive, and emotional behaviors. Dysfunction of dopamine system in this area is implicated… 
2017
2017
TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington’s Disease
Huntington’s disease (HD) is characterized by progressive loss of striatal medium spiny neurons (MSNs) that constitute direct and… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models
Cognitive deficits in various domains, including recognition memory, attention, impulsivity, working memory, and executive… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms
Phosphodiesterase 10A (PDE10A) inhibitors are expected to be novel drugs for schizophrenia through activation of both direct and… 
  • table 1
  • figure 1
  • figure 3
2016
2016
A human [11C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor
Phosphodiesterase 10A (PDE10A) is selectively expressed in the striatal regions in the brain and may play a role in modulating… 
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
2016
2016
Brain PET measurement of PDE10A occupancy by TAK‐063, a new PDE10A inhibitor, using [11C]T‐773 in nonhuman primates
Because phosphodiesterase 10A (PDE10A) degrades both cyclic adenosine monophosphate and cyclic guanosine monophosphate and is… 
2015
2015
In Vivo Pharmacological Characterization of TAK-063, a Potent and Selective Phosphodiesterase 10A Inhibitor with Antipsychotic-Like Activity in Rodents
Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor
Phosphodiesterase 10A (PDE10A) inhibition is a novel and promising approach for the treatment of central nervous system disorders… 
  • table 1
  • table 2
  • table 2
  • figure 1
  • figure 2
2014
2014
Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A…
A novel series of pyridazinone-based phosphodiesterase 10A (PDE10A) inhibitors were synthesized. Our optimization efforts using… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE